. This sCD27, which has an extensiv structural homology to the 55-kD transmembrane m~l e c u l e ,~~~ can also be detected in body fluids like plasma, urine, and spinal At present the function of CD27 is not known. However, CD27 belongs to the nerve growth factor receptor (NGF-R) family,' a number of structural homologous molecules including the two TNF receptors,lO-'* the B-cell antigen CD40,I3 the lymphocyte activation antigen CD30,I4 and FAS/APO-1, a molecule expressed on a number of cell lines and on activated T and B cells.15 Very recently the ligand of CD27 has been identified.16 Its sequence suggests that it is a type 2 transmembrane protein with similarities to three other homologous ligands of the NGF-R family," ie, tumor necrosis factor-a (TNF-a) and TNF-P, and gp39, the ligand of CD40." Members of the NGF-R family appear to be involved in the selection of lymphoid cells. In vitro CD40 antibodies prevent apoptosis of germinal center B cells, indicating an important role for the CD40-CD40 ligand pair in antigen-dri- 
C kD homodimer present on mature thymocytes, on the vast majority of both CD4' and CD8+ peripheral blood T and on a subset of B cell^.^.^ Activation of T cells via the TCR/CD3 complex results in upregulation of CD27 expression on the cell membrane as well as in the release of a soluble 28-to 32-kD form of CD27 (sCD27). This sCD27, which has an extensiv structural homology to the 55-kD transmembrane m~l e c u l e ,~~~ can also be detected in body fluids like plasma, urine, and spinal
At present the function of CD27 is not known. However, CD27 belongs to the nerve growth factor receptor (NGF-R) family,' a number of structural homologous molecules including the two TNF receptors,lO-'* the B-cell antigen CD40,I3 the lymphocyte activation antigen CD30,I4 and FAS/APO-1, a molecule expressed on a number of cell lines and on activated T and B cells. 15 Very recently the ligand of CD27 has been identified. 16 Its sequence suggests that it is a type 2 transmembrane protein with similarities to three other homologous ligands of the NGF-R family," ie, tumor necrosis factor-a (TNF-a) and TNF-P, and gp39, the ligand of CD40." Members of the NGF-R family appear to be involved in the selection of lymphoid cells. In vitro CD40 antibodies prevent apoptosis of germinal center B cells, indicating an important role for the CD40-CD40 ligand pair in antigen-dri- ven B-cell se1ecti0n.l~ Recently, mutations in the CD40 ligand have been shown to be responsible for the hyper-IgM syndrome, illustrating the in vivo importance of CD40 in B-cell maturation." APO-I might also have a function in the regulation of lymphocyte survival because cross-linking of APO-1 by an anti-APO-1 monoclonal antibody (MoAb) induces apopt~sis.'~ In view of the structural homologies with these receptor-ligand pairs, CD27 and its ligand may also play a role in the regulation of differentiation and/or selection of lymphocyte populations.
B-cell leukemias and lymphomas are useful for the study of differentiation-stage-related expression of antigens. In this report we describe the expression of CD27 on human malignant B cells. Moreover, we show that very high amounts of soluble CD27 are sometimes present in the sera of patients with B-cell malignancies and the existence of a close correlation between sCD27 in serum and tumor load.
MATERIALS AND METHODS
Tissues. Normal and pathologic lymphoid tissues were selected from the files of the Department of Pathology, Academic Medical Center, University of Amsterdam, The Netherlands. Non-Hodgkin's lymphomas were classified according to the International Working Formulation (WF).2' Expression of T-and B-lineage markers was used for classification as T-or B-cell lymphomas.
Preparation and separation ofcell suspensions. Normal peripheral blood mononuclear cells were obtained by Ficoll-Isopaque (Organon Teknika Corp, Durham, UK) density gradient centrifugation (density = 1.077 g/cm3) of EDTA blood from healthy volunteers. In some experiments we used purified normal tonsillar B cells. Freshly obtained normal tonsillar tissue was dissected free from surface epithelium and finely minced into a cell suspension. Mononuclear cells were isolated by Ficoll-Isopaque density gradient centrifugation. Monocytes were removed by plastic adherence (1 hour at 37°C in 10 cmz Petri dishes [Costar, Cambridge, MA]). T cells were depleted using 2-aminoethyl-isothiouronium bromide-modified sheep red blood cells (SRBCs). The purified B cells were then layered on a Percoll gradient (Pharmacia, Uppsala, Sweden) consisting of five density layers ( biopsies of patients with B-cell malignancies. For the studies on the expression of CD27 on B-cell precursors we used normal BM aspirated from patients undergoing cardiac surgery or from patients with lymphoma whose BM was obtained for clinical staging and was found to be free from disease. BM mononuclear cells were isolated by Ficoll-Isopaque density gradient centrifugation. Informed consent from patients and healthy volunteers was obtained according to the rules of our hospital.
Immunocytology. The phenotype of the cell suspensions was determined by fluorescence-activated cell sorter (FACS) analysis using the following MoAbs in an indirect immunofluorescence technique: CLB-CD313, CLB-CD41 I , CLB-CD5, CLB-CD8/4, CLB-CD 10, CLB-CD 19, CLB-CD20, CLB-Blast-2(CD23), CLB-CD24, CLB-IL2R/I(CD25), CLB-CD27/1, anti-IgM(MH 15), antiIgG(MH 16), all produced at the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, and clustered in the international workshops on leukocyte differentiation antigens. Anti-K, anti-A, anti-IgD, and CD22 were purchased from DAKO (Glostrup, Denmark). Binding of the antibodies was visualized with fluorescein isothiocyanate (F1TC)-labeled poloclonal goat-antimouse IgG (GAM). In some double-labeling experiments we used CDI 9-phycoerythrine (PE) from Becton Dickinson (BD; Sunnyvale, CA). To block free binding sites on GAM antibodies, cells were incubated with normal mouse serum and washed before addition of CD19-PE. In studies with the purified tonsillar B cells we used goat-antimouse-PE (Southern Biotech. Assoc. Inc, Birmingham, AL) and PNA-FITC (Sigma, St Louis, MO). In the triple-labeling experiments peripheral blood mononuclear cells were incubated with CD27-FITC (CLB), CD5-PE (BD), and biotinylated CD 19 (CLB). After washing, Cychrome-labeled streptavidine (ITK Diagnostics, Uithoorn, The Netherlands) was added. In the triplelabeling experiments with BM mononuclear cells we used two different combinations of MoAbs during the first incubation step: ( I ) CD34-FITC (CLB), CD19-PE (BD), and biotinylated CD27 (CLB); (2) CDIO-PE (BD), biotinylated CD19 (CLB), and CD27-FITC (CLB). PERCP-labeled streptavidine (BD) was added after washing. Staining with irrelevant isotype-matched antibodies was always used as control. Immirnohistochemistry. Immunoperoxidase staining was performed as described previously.22 In brief, cryostat sections were fixed in aceton for IO minutes, washed in phosphate-buffered saline (PBS), and preincubated with normal goat serum (10% in PBS). After preincubation the sections were incubated with the primary antibody for I hour. .OOO 1). In triple-labeling experiments CD27 was found to be confined to the CD19+CD5-B cells (n = 3) (Fig 1B) . In histologic sections of normal tonsils CD27' cells were abundantly present in the T-cell areas (Fig 2A) . In contrast, significant numbers of CD27' B cells were only found in the germinal center (Fig 2, A and B) . Similar data were obtained in lymph nodes and spleen (not shown). Restriction of CD27 expression to the germinal center B cells in the secondary lymphoid organs was also demonstrated in expenments with suspensions of purified normal tonsil B cells. These cells were separated into high-and low-density B cells and analyzed for expression of CD27 and peanut agglutinin (PNA). As shown in Fig 1 (C and D) the vast majority of CD27' B cells were found within the low-density PNA' cells. These cells were also CD19' and I@-, a phenotype consistent with follicular center cells (data not shown). blocked by 0.3% H,O, in methanol. All antibodies were titrated to give optimal staining results. For detection, a streptavidine-biotinperoxidase complex (DAKO) was used. After incubation for 30 minutes the sections were incubated in 3,3-amino-9-ethyl carbazole (Sigma) for 10 to 20 minutes.
Soluble CD27 enzyme-linked immunosorbent assay (ELISA). sCD27 serum levels were determined by ELISA using two CD27 MoAbs directed against nonoverlapping epitopes (sandwich ELISA), essentially as described before.7ss CLB-CD27/ 1 and CLB-CD27/3 (both IgG2a) were purified from axites by protein A affinity chromatography. CLB-CD27/ 1 was biotinylated according to standard procedures. The ELISA was performed in 96-well plates (Maxisorb; Nunc, Roskilde, Denmark) precoated for 2 hours at 37°C with 100 pL of CLB-CD27/3 (5 pg/mL) in PBS (pH 7.4). The concentration of sCD27 was expressed as units per milliliter, by reference to a standard curve obtained from absorbance values of serial dilutions of pooled plasma of 15 healthy blood donors. The amount of sCD27 in pooled plasma was arbitrarily set at 100 U/ mL. The lower detection limit of this assay is 2 U/mL. In initial experiments it was found that neither source (plasma v serum) nor storage affected sCD27 levels.
Because of the known effect of renal dysfunction on serum sCD27 levels: patients with a serum creatinin exceeding 100 pmol/ L were excluded from analysis. The sera tested were separated from the blood immediately after coagulation and stored at -30°C until Statislical analysis. The sCD27 data were analyzed by the Mann-Whitney U-test. Table 1 . It can be seen that CD27 is already present on malignant B cells corresponding to the early stages of antigen-independent B-cell maturation. Although all four pro-B acute lymphocytic leukemia (ALL) (CD34+/CD 19+/CD 1 O-/TdT+) tested were CD27-, CD27 was present on 4 of 17 pre-pre-B ALL (CD19+/CD10+/ cIgM-/TdT+), and 2 of 3 pre-B ALL (CDI9+/CD10+/ cIgM+/TdT+). The two B-ALLs tested (CD 19+/CD 1 Of/ mIgM+/TdT-) had a high expression of membrane-bound CD27. Variable, but in general moderate to strong, expression was found on chronic lymphocytic leukemia (CLL) cells, prolymphocytic leukemia, and two of four hairy cell leukemias. Immunohistochemical analysis of non-Hodgkin's lymphomas (NHLs) showed a moderate to high expression of CD27 in most low-grade diffuse and follicular lymphomas and a highly variable expression on intermediate-and high-grade lymphomas (see Fig 2, C and D, and Table 2 ). Myeloma cells were found to lack membrane expression of CD27 (n = 6).
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RESULTS
Expression of
Serum levels of soluble CD27 in patients with B-cell malignancies.
By means of an ELISA sCD27 levels were measured in sera from groups of untreated patients with U/mL) of the control group (Fig 3) . However, striking differences were observed between different groups. Very high levels (up to 6,000 U/mL) of sCD27 were found in sera from patients with CLL. In patients with NHLs serum sCD27 concentrations in those with low-grade lymphomas were significantly higher than in those with intermediate and high-grade lymphomas (P < .0001 and P -= .0035, respectively) (Fig 4) . sCD27 levels in low-grade NHL were not significantly different from those in CLL (P = .42). In the few T-cell malignancies tested (3 ALL and 2 NHL), sCD27 levels were only moderately increased: range 278 to 684 U/mL. In CLL a correlation was found between stage (Raj classification) and serum sCD27 (Fig 5) . Similarly, within this group of patients there was a correlation between sCD27 and the absolute number of circulating lymphocytes (r = .79; data not shown). The possible correlation between clinical stage and sCD27 could not be investigated in NHL because the vast majority of patients in this series had NHL stage 3 or 4 (Ann Arbor). In five patients we had the opportunity to study sCD27 levels longitudinally. In all these patients (four with NHL and one with pre-pre B-ALL) CD27 serum levels matched clinical disease activity cq tumor load: increased levels at diagnosis and relapse and normal levels during remission. Two examples are shown in Fig 6. A dramatic change in the levels of sCD27 could be observed in a patient with a villous splenic lymphoma who, only partially responding to chemotherapy, underwent a splenectomy. After removal of the very sCD27 is related to tumor load.
weight approximately 4 kg) sCD27 almost normalized within 24 hours (Fig 7) , reflecting not only the amount of tumour reduction obtained but also indicating that sCD27 has a plasma half-life time of less than 8 hours.
We studied only one patient with a T-cell malignancy longitudinally. In this T-ALL patient the sCD27 normalized rapidly during chemotherapy and remained so during complete remission (1.5 years) (data not shown).
DISCUSSION
The two key observations in this study are: (1) membrane-bound CD27 is present on malignant B cells representative of almost all stages of B-cell ontogeny, and (2) soluble CD27 can be detected in the serum of many patients with B-cell malignancies and can be used as a marker for tumor load.
Initial studies suggested that the expression of CD27 was confined to a (major) subset of T lymphocytes and thymocytes.L,2 More recently CD27 was also shown to be present on a subpopulation of mature B cells3 and natural killer cells. 23 An important question is whether the observed CD27 expression on malignant B cells representing almost all of the stages of the antigen-independent and -dependent B-cell development is a reflection of its expression during normal B-cell ontogeny. This is probably not the case because we were unable to show CD27 expression on normal BM B-cell precursors up to and including the pre-B cell stage. Aberrant CD27 expression on malignant B cells is also suggested by our data on CLL cells: these pathologic B cells are CD27+, whereas their supposed normal counterparts in the follicle mantle zone27 are CD27-. Likewise, in triple-labeling experiments we found that CD5+ peripheral blood B cells are CD27-. Furthermore, cord blood B cells, containing a large proportion of CD5+ cells,28 have been reported to be CD27 negati~e.~ The same argument holds for the observed (weak to moderate) CD27 expression on Burkitt's lymphoma cells and the absence of CD27 on their putative normal counterparts in the germinal center basal dark ~o n e .~~,~' The mechanism and functional significance of aberrant CD27 expression on malignant B cells remains to be elucidated.
Our findings with respect to the soluble form of CD27 indicate that in patients with B-cell malignancies, serum levels of sCD27 are correlated to disease activity cq tumor load. The lower sCD27 levels in intermediate-/high-grade NHL in comparison with CLL/low-grade NHL can be explained both by the in general lower membrane expression of CD27 and the lower absolute tumor load. Although suggestive, the limited number of observations as well as the (in)frequency of serum sampling in our study do not yet allow for conclusions as to predictive value of sCD27 determinations. Our data strongly suggest that the sCD27 is derived from the malignant B cells. However, we could not prove this because immunoprecipitation studies did not show differences between the sCD27 from the serum of the two patients tested (CLL and low-grade NHL) and a culture supernatant of CD3-stimulated T lymphocytes (data not shown). Hence, the increased sCD27 levels could reflect Tcell activation as has been shown during acute cytomegalovirus and human immunodeficiency virus infections, in synovial fluid of RA patients and in the cerebrospinal fluid of multiple sclerosis patient^.^.^^^^^^ There are several arguments against this possibility. First, the sCD27 levels in patients with B-cell malignancies are not only much higher than those reported in the patients with acute or chronic T-cell a~tivation,~",~,~' but they also correlated with disease stage, as illustrated for CLL in Fig 5. Secondly, the splenectomy of a patient with a splenic NHL resulted in a rapid and permanent decrease in sCD27. Finally, production of sCD27 could be shown in the culture supernatant of purified CLL-B cells (< 1 % CD3+ cells; data not shown).
The mechanism of the generation of sCD27 by the malignant B cells is not yet known. Studies in T cells have indicated that membrane-bound and soluble CD27 have a common mRNA and protein precursor, and that sCD27 is generated from the membrane-bound CD27 by proteolys~s .~~ This process is strongly enhanced by T-cell activation. In vitro studies with B cells have shown that activation of CD27-B cells by staphylococcus aureus Cowan (SAC) and interleukin-2 can induce expression of membrane bound CD27.3 Under these conditions these B cells release soluble CD27 (R.Q.H., unpublished observations). However, in malignant B cells regulation of membrane expression and release of CD27 might be different from that in normal T and B cells. This is suggested by our unpublished observations that purified CLL-B cells, cultured for 4 days without any stimulation, release sCD27 into the supernatant. Neither this release nor membrane expression of CD27 were influenced by addition of PMA and TNF, a combination shown to induce strong proliferation of CLL cells.33
If membrane-bound CD27 is involved in the functional activity of the CD27+ T and B lymphocytes, the presence of high amounts of soluble CD27 in the plasma might interfere with these functions. It would be interesting to investigate whether sCD27 contributes to the impaired cellular and humoral immunity and autoimmune phenomena frequently observed within this group of patients. 
